Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-𝜷 in mild cognitive impairment but not in Alzheimer’s disease

Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-𝜷 in mild cognitive impairment but not in Alzheimer’s disease

Apolipoprotein E is the most well-established genetic risk factor for Alzheimer’s disease. However, the associations of apolipoprotein E with tau pathology and cognition remain controversial. The research checks the hypothesis that the relationships between apolipoprotein E alleles and cerebrospi...

Full description

Bibliographic Details
Main Authors:	Feng Xing, Tao Meng, Joseph Therriault, Jing Luo, Hua Zhang, Alzheimer’s Disease Neuroimaging Initiative
Format:	Article
Language:	English
Published:	IMR Press 2021-06-01
Series:	Journal of Integrative Neuroscience
Subjects:	alzheimer's disease amyloid-β apolipoprotein e mild cognitive impairment tau
Online Access:	https://jin.imrpress.com/fileup/1757-448X/PDF/1625014726838-1248727081.pdf

Similar Items

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
by: Anna Rubinski, et al.
Published: (2020-10-01)

Impact of amyloid and tau positivity on longitudinal brain atrophy in cognitively normal individuals
by: Motonobu Fujishima, et al.
Published: (2024-04-01)

Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment
by: Giulia Arenare, et al.
Published: (2023-08-01)

Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease
by: Kazushi Suzuki, et al.
Published: (2020-01-01)

A Case of Cerebral Amyloid Angiopathy-Related Inflammation With the Rare Apolipoprotein ε2/ε2 Genotype
by: Yin-Yan Xu, et al.
Published: (2019-05-01)

APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
by: Susan Abushakra, et al.
Published: (2020-01-01)

Decreased Global EEG Synchronization in Amyloid Positive Mild Cognitive Impairment and Alzheimer’s Disease Patients—Relationship to <i>APOE ε4</i>
by: Una Smailovic, et al.
Published: (2021-10-01)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
by: Lauren E. McCollum, et al.
Published: (2021-01-01)

Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS)
by: Tyler S. Saunders, et al.
Published: (2022-09-01)

Association of CSF GAP-43 and <i>APOE</i> ε4 with Cognition in Mild Cognitive Impairment and Alzheimer’s Disease
by: Yueli Zhu, et al.
Published: (2022-12-01)

Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
by: Gustavo Patow, et al.
Published: (2023-12-01)

Learning deficit in cognitively normal APOE ε4 carriers with LOW β‐amyloid
by: Yen Ying Lim, et al.
Published: (2021-01-01)

Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease
by: Yue Cai, et al.
Published: (2023-02-01)

Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer’s disease
by: Omar A. Halawa, et al.
Published: (2019-01-01)

A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer’s Disease
by: Yunxing Ma, et al.
Published: (2022-07-01)

Association of pancreatic polypeptide with mild cognitive impairment varies by APOE ε4 allele
by: Rosebud O. Roberts, et al.
Published: (2015-09-01)

Sex differences in the association between apolipoprotein E ε4 allele and Alzheimer's disease markers
by: Erin E. Sundermann, et al.
Published: (2018-01-01)

Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals
by: Davina Biel, et al.
Published: (2021-08-01)

The Relationship Between Hippocampal Volumes and Delayed Recall Is Modified by APOE ε4 in Mild Cognitive Impairment
by: Xiwu Wang, et al.
Published: (2019-02-01)

Plasma adiponectin levels predict cognitive decline and cortical thinning in mild cognitive impairment with beta-amyloid pathology
by: Keun You Kim, et al.
Published: (2022-11-01)

Staging of amyloid β, t‐tau, regional atrophy rates, and cognitive change in a nondemented cohort: Results of serial mediation analyses
by: Evan Fletcher, et al.
Published: (2018-01-01)

Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease
by: Min Seok Baek, et al.
Published: (2020-10-01)

The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment
by: Hyung-Ji Kim, et al.
Published: (2022-07-01)

Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment
by: Nor A. Samat, et al.
Published: (2017-12-01)

Identification of an APOE ε4–specific blood‐based molecular pathway for Alzheimer's disease risk
by: Qiushan Tao, et al.
Published: (2023-10-01)

Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer’s disease
by: Zhi-Bo Wang, et al.
Published: (2022-12-01)

High Glycemic Load Is Associated with Cognitive Decline in Apolipoprotein E ε4 Allele Carriers
by: Mélissa Gentreau, et al.
Published: (2020-11-01)

Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis
by: Zsolt Huszár, et al.
Published: (2024-04-01)

Language dysfunction correlates with cognitive impairments in older adults without dementia mediated by amyloid pathology
by: Chunchen Xiang, et al.
Published: (2023-05-01)

Overview of the Molecular Modalities and Signaling Pathways Intersecting with β-Amyloid and Tau Protein in Alzheimer’s Disease
by: Ahmed M. Elshazly, et al.
Published: (2023-07-01)

Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
by: Ching-Chi Hsu, et al.
Published: (2024-03-01)

The Effect of Apolipoprotein E ε4 (APOE ε4) on Visuospatial Working Memory in Healthy Elderly and Amnestic Mild Cognitive Impairment Patients: An Event-Related Potentials Study
by: Li-Hua Gu, et al.
Published: (2017-05-01)

APOEε4 Carriers Exhibit Objective Cognitive Deficits: A Cross-Sectional Study in a Single Center Trial
by: Yanfang Zeng, et al.
Published: (2024-03-01)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
by: Lawren VandeVrede, et al.
Published: (2020-01-01)

Overlap Between Apolipoprotein Eε4 Allele and Slowing Gait Results in Cognitive Impairment
by: Ryota Sakurai, et al.
Published: (2019-09-01)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
by: Taylor J. Maxwell, et al.
Published: (2018-08-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-06-01)

Ginseng intake and Alzheimer disease-specific cognition in older adults according to apolipoprotein ε4 allele status
by: Boung Chul Lee, et al.
Published: (2023-04-01)

AD Resemblance Atrophy Index of Brain Magnetic Resonance Imaging in Predicting the Progression of Mild Cognitive Impairment Carrying Apolipoprotein E-ε4 Allele
by: Yingren Mai, et al.
Published: (2022-04-01)

Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment
by: Jung-Min Pyun, et al.
Published: (2021-08-01)